Business Context and Reporting Period
Company: Access Pharmaceuticals, Inc. (Note: Request metadata listed "Abeona Therapeutics," but the filing text identifies the registrant as Access Pharmaceuticals, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: An emerging biopharmaceutical company focused on nanopolymer chemistry and drug delivery technologies. The company has one FDA-approved product (MuGard for oral mucositis) and a pipeline including ProLindac (Phase 2/3), Pexiganan (Phase 3), and several pre-clinical candidates. The company operates with a strategy of out-licensing assets to fund internal development.
Key Financial Metrics
| Metric | 2008 | 2007 |
|---|---|---|
| Total Revenues | $291,000 | $57,000 |
| Net Loss (Common Stockholders) | $(20,573,000) | $(36,652,000) |
| Loss Per Share (Basic & Diluted) | $(3.51) | $(10.32) |
| Research & Development Expenses | $12,613,000 | $2,602,000 |
| General & Administrative Expenses | $4,340,000 | $4,076,000 |
| Cash and Cash Equivalents (Dec 31, 2008) | $2,663,000 | $6,921,000 |
| Working Capital Deficit (Dec 31, 2008) | $(1,356,000) | $6,239,000 (Surplus) |
| Long-Term Debt | $5,500,000 | $5,500,000 |
| Accumulated Deficit | $(134,897,000) | $(114,324,000) |
Liquidity: The company reported a net cash burn rate of approximately $505,000 per month for 2008. Management projected resources would fund operations into the first quarter of 2010.
Material Changes vs. Prior Period
- Revenue Increase: Total revenue increased to $291,000 from $57,000, driven by licensing revenues ($118,000 vs. $23,000) and sponsored research ($173,000 vs. $34,000).
- R&D Expense Surge: R&D expenses jumped to $12.6 million from $2.6 million. This was primarily due to a one-time non-cash charge of $8.879 million for in-process research and development (IPR&D) acquired in the Somanta Pharmaceuticals acquisition in Q1 2008.
- Reduced Net Loss: Net loss decreased by approximately $16 million compared to 2007. The 2007 loss included a $11.6 million loss on the extinguishment of debt and $14.6 million in preferred stock dividends related to beneficial conversion features, neither of which occurred in 2008.
- Working Capital Deterioration: The company moved from a working capital surplus of $6.2 million in 2007 to a deficit of $1.36 million in 2008, reflecting operating cash outflows and the acquisition of Somanta.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance:
- Management expects to incur additional operating losses over the next several years.
- Projected net cash burn rate for the next twelve months is approximately $115,000 per month.
- Capital resources are expected to be sufficient only through the first quarter of 2010; substantial additional capital will be required.
Risks and Contingencies:
- Going Concern: The independent auditor included an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern due to recurring losses and liquidity position.
- Internal Controls: Management identified a material weakness in internal control over financial reporting due to a lack of segregation of duties (all financial reporting performed by the CFO) and insufficient accounting staff.
- Liquidated Damages: The company accrued $675,000 in potential liquidated damages for failing to maintain an effective registration statement for Series A Preferred Stock holders.
- Acquisition Integration: The company closed the acquisition of MacroChem Corporation on February 25, 2009 (subsequent to year-end), which introduces integration risks.
Unusual Items:
- Preferred Stock Dividends: $3.358 million in preferred stock dividends were recorded in 2008, including $857,000 related to a beneficial conversion feature on Series A Preferred Stock issued in February 2008.
- Debt Extinguishment (2007): The 2007 period included a significant non-cash loss on debt extinguishment ($11.6 million) which is not present in 2008.
Investor Verification Checklist
- Cash Runway: Verify current cash balances and burn rate to confirm if the company has secured financing to extend operations beyond Q1 2010.
- MacroChem Acquisition: Review the final purchase price allocation and integration status of the MacroChem Corporation acquisition closed in February 2009.
- Internal Controls: Assess the remediation plan for the material weakness in internal controls regarding financial reporting segregation of duties.
- Liquidated Damages: Confirm the status of the registration statement for Series A Preferred Stock to determine if the accrued $675,000 in liquidated damages will be paid or waived.
- ProLindac Development: Monitor the progress of Phase 2/3 trials for ProLindac and the status of licensing agreements with partners in China and Korea.